Impax/Teva Wellbutrin SR Generic Cleared To Launch By Court, FDA
Executive Summary
Impax' bupropion sustained-release generic is cleared for launch following an appeals court ruling that the company does not infringe GlaxoSmithKline's Wellbutrin SR/Zyban patent
You may also be interested in...
Eon Wellbutrin SR Generic Launch Delayed By Two Restraining Orders
Eon's launch of generic bupropion extended-release 100 mg (GlaxoSmithKline's Wellbutrin SR) depends on the resolution of two temporary restraining orders: one from GSK and one from Andrx
Patent Infringement Claims Clarified In Festo Ruling
A federal appeals court decision in the Festo case further clarifies the circumstances under which pharmaceutical patent holders can assert infringement claims under the doctrine of equivalents
Wellbutrin SR Patent Needs Further Review, Appeals Court Agrees With GSK
An appeals court ruling for GlaxoSmithKline in Wellbutrin SR patent litigation against Andrx finds the district court erred in its construction of GSK's patent claims